Product Data Sheet

Pacific Blue™ anti-mouse IL-10

Catalog # / Size: 3125095 / 25 μg

3125100 / 100 µg

Clone: JES5-16E3
Isotype: Rat IgG2b, κ

Immunogen: E. coli-expressed, recombinant mouse

IL-10

Reactivity: Mouse

Preparation: The antibody was purified by affinity


chromatography, and conjugated with Pacific Blue™ under optimal conditions. The solution is free of unconjugated

Pacific Blue™.

Formulation: Phosphate-buffered solution, pH 7.2,

containing 0.09% sodium azide.

Concentration: 0.5



Th2 polarized C57BL/6 splenocytes stained with JES5-16E3 Pacific Blue™ and CD3 (17A2) PE

Applications:

Applications: Flow Cytometry

Recommended Usage:


Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this

staining, the suggested use of this reagent is ≤ 1.0 microg per 106 cells in 100 microL volume or 100 microL of whole blood. It is recommended that the reagent be titrated for optimal

reagent be titrated for optimal performance for each application.

* Pacific Blue™ has a maximum emission of 455 nm when it is excited at 405 nm. Prior to using Pacific Blue™ conjugate for flow cytometric analysis, please verify your flow cytometer's capability of exciting and detecting the

fluorochrome.



Th2 polarized C57BL/6 splenocytes stained with rat IgG2b isotype Pacific Blue™ and mouse CD3 antibody (17A2) PE

Application Notes:

ELISA or ELISPOT Detection 1,9,11:

The biotinylated JES5-16E3 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified JES5-2A5 antibody (Cat. No. 504902/504904) as the capture antibody.

Neutralization¹⁴: The LEAF™ purified JES5-16E3 antibody can neutralize the bioactivity of natural or recombinant IL-

Flow Cytometry3: The fluorochrome-

labeled JES5-16E3 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IL-10-producing cells within mixed cell populations.

Additional reported applications (for relevant formats) include:

immunohistochemistry3.

Application References:

- 1. Simkin G, et al. 2000. J. Immunol. 164:2457.
- 2. Kitagaki K, et al. 2002. Clin. Diagn. Lab Immunol. 9:1260.
- 3. Khanna A, et al. 2000. J. Immunol. 164:1346.
- 4. Sander B, et al. 1993. J. Immunol. Methods 166:201.
- 5. Litton M, et al. 1994. J. Immunol. Methods 175:47.
- 6. Andersson U, et al. 1999. Detection and qunatification of gene expression. New York:Springer-Verlag.
- 7. Finkelman F, et al. 2003. Curr. Prot. Immunol. John Wiley & Sons New York. Unit 6.28.
- 8. Wang W, et al. 2004. FASEB J. 18:1043.
- 9. Brummel R and Lenert P. 2005. J. Immunol. 174:2429.
- 10. Lawson BR, et al. 2007. J. Immunol. 178:5366.
- 11. Xu G, et al. 2007. J. Immunol. 179:5358. PubMed
- 12. Brummel R, et al. 2005. J. Immunol.174:2429. PubMed
- 13. Kang YJ, et al. 2007. Stem Cells 25:1814. PubMed
- 14. Seo N, et al. 2001. Immunology. 103:449. (Neut)

Description:

IL-10 was originally described as Cytokine Synthesis Inhibitory Factor (CSIF) by virtue of its ability to inhibit cytokine production by Th1 clones. IL-10 shares over 80% sequence homology with the Epstein-Barr virus protein BCRFI. IL-10 inhibits IFN- γ , TNF- β , and IL-2 production by Th1 clones; inhibits macrophage-mediated IL-1, IL-6, and TNF- α synthesis; suppresses the delayed type hypersensitivity response; stimulates Th2 cell response (which results in elevated antibody production); and promotes mast cell proliferation in combination with IL-4.

Antigen References:

- 1. Fitzgerald K, *et al.* Eds. 2001. The Cytokine FactsBook. Academic Press San Diego.
- 2. de Waal-Malefy R, et al. 1992. Curr. Opin. Immunol. 4:314.
- 3. Howard M, et al. 1992. Immunol. Today 13:198.